The outcome that matters changes in this decade. At 45 the question is how long the healthy stretch runs. At 70 it is whether next year looks like this one — whether you carry your own shopping, drive at night, get off the floor unaided, and follow a conversation in a restaurant. Those are the things that decide where and how you live, and they are more modifiable than most people assume.
The risk profile changes too. Absolute risk is at its highest, which means the absolute benefit of a given intervention is also at its highest. But the cost of a single adverse event — a fall, a fracture, a hospitalisation, a delirium episode — is far greater than at any earlier age. That asymmetry is what should reorder the priority list, and it is why muscle and balance sit above almost everything else here.
The Verdict
Interventions ranked by effect on independence
| Intervention | Leverage | Why it ranks here |
|---|---|---|
| Resistance training, 2–3 sessions a week | Very high | Muscle mass falls roughly 3–8% per decade after 30 and the rate accelerates after 60. Strength training reverses part of that at any age, and muscle and balance are the strongest modifiable predictors of continued independence |
| Balance and gait work | Very high | Around one in four adults over 65 falls each year, and hip fracture carries substantial one-year mortality. Balance training is one of the few interventions with direct evidence for fall reduction |
| Blood pressure control | Very high | Intensive control reduced cardiovascular events and mortality in adults over 75 in the SPRINT trial. Also the most consistent modifiable factor in cognitive decline |
| Protein at 1.0–1.2 g per kg body weight, spread across meals | High | Older adults have a blunted muscle-protein response to a given protein dose, so both total intake and per-meal distribution matter more than they did at 40 |
| Hearing and vision correction | High | Both are independently associated with cognitive decline and with falls. The ACHIEVE trial found hearing intervention slowed cognitive decline in participants at higher baseline risk |
| Guideline-based cancer screening | High | Colonoscopy, mammography, lung CT for eligible smokers, and a one-time abdominal aortic ultrasound for men 65–75 who ever smoked. These have trial evidence; whole-body scans do not |
| Medication review and deprescribing | High | Polypharmacy drives falls, confusion and hospitalisations. An annual review against the Beers criteria removes risk rather than adding an intervention |
| Vaccination — shingles, pneumococcal, RSV, influenza, COVID | High | Among the cheapest available reductions in hospitalisation risk in this decade, and routinely skipped |
| ApoB and lipid management | Moderate to high | Absolute risk is highest here, so the absolute benefit of lowering it is largest. The relative benefit is similar to younger ages |
| Social connection and purpose | Moderate to high | Consistently associated with mortality and cognitive outcomes in observational data. Not a supplement question, and not a small one |
| Bone density assessment and treatment | Moderate to high | DEXA identifies who benefits from treatment. Fracture prevention is where the loss-of-independence risk concentrates |
| Whole-body MRI and multi-cancer blood screening | Uncertain | Not recommended by screening guidelines for asymptomatic adults. Incidental findings are common and lead to further testing. Reasonable to consider with specific risk factors, after a conversation about what a result would change |
Resistance training belongs at the top for a reason that is easy to state and easy to underweight. Sarcopenia is the mechanism that converts ageing into dependence, and it responds to training at every age studied, including in nursing-home populations in their 90s. No supplement, scan or hormone on this page has a comparable effect on whether you can stand up from a chair unaided in ten years.
The markers worth tracking
The panel shifts in this decade. Some markers matter more, some targets loosen rather than tighten, and two of the most predictive measures are physical rather than biochemical.
| Marker | Range or target | Why it matters here |
|---|---|---|
| ApoB and full lipid panel | ApoB under 80 mg/dL for average risk; lower with established disease | Absolute cardiovascular risk peaks in this decade, so the absolute benefit of lowering particle count is at its largest |
| Lp(a), once in a lifetime | Under 75 nmol/L (about 30 mg/dL) | Genetically set and never repeated. Elevated Lp(a) raises the urgency of controlling everything modifiable |
| Home blood pressure average | Individualised; intensive targets benefited adults over 75 in trial data | Standing readings matter here too — orthostatic drops cause falls, and are a reason to individualise the target |
| HbA1c and fasting glucose | Targets are individualised with age and comorbidity | Tight control has a different risk-benefit balance in older adults, where hypoglycemia itself causes falls and confusion |
| Creatinine with eGFR, and albumin-to-creatinine ratio | eGFR above 60; ACR under 30 mg/g | Kidney function determines the safe dosing of many medications, and albuminuria is an early cardiovascular and renal signal |
| CBC, ferritin, B12, folate | Ferritin above 30 ng/mL; B12 above 300 pg/mL | Anemia and B12 deficiency both produce fatigue, unsteadiness and cognitive symptoms, and both are correctable. B12 absorption falls with age and with metformin use |
| TSH with free T4 | TSH roughly 0.4–4.0 mIU/L | Thyroid disease is common in this decade and presents atypically — sometimes as apathy or cognitive change rather than classic symptoms |
| Vitamin D and calcium | Vitamin D commonly targeted at 30–50 ng/mL | Relevant to bone density and fall risk, and deficiency is common with less sun exposure and reduced skin synthesis |
| Albumin and body composition | Albumin 3.5–5.0 g/dL | Low albumin and falling lean mass are markers of the frailty trajectory, and both are actionable through protein and training |
| DEXA bone density | T-score above -1.0 is normal; -2.5 or below is osteoporosis | Identifies who benefits from treatment. Recommended for women 65 and over, and for men and younger women with risk factors |
| Grip strength and gait speed | Gait speed under 0.8 m/s signals elevated risk | Two free bedside measures that predict disability and mortality as well as most blood tests, and are almost never recorded |
Two entries run against the usual direction of travel. HbA1c targets in older adults are individualised and often looser, because hypoglycemia causes falls and confusion and those carry more immediate risk than a slightly higher average glucose. And blood pressure should be measured standing as well as sitting, because an orthostatic drop is a fall risk that an aggressive target can create.
What guideline screening already covers
A large share of the highest-value testing at this age is established, evidence-backed, and covered by Medicare. It is also frequently overdue in people who are simultaneously paying out of pocket for unproven scans.
- Colorectal cancer screening through age 75, with individualised decisions from 76 to 85
- Mammography on the schedule your clinician recommends, generally through the mid-70s
- Low-dose CT for lung cancer in adults 50–80 with a qualifying smoking history
- A one-time abdominal aortic aneurysm ultrasound for men aged 65–75 who have ever smoked
- DEXA bone density for women 65 and over, and for men and younger women with risk factors
- Vaccination against shingles, pneumococcal disease, RSV, influenza and COVID
- An annual medication review, which removes risk rather than adding an intervention
Platform options
Three categories, all listed alphabetically. Ordering carries no editorial meaning. Note that none of these replaces the covered screening above.
Diagnostic-only platforms, alphabetically
| Platform | Price | What you get |
|---|---|---|
| Function Health | ~$499/yr membership | Broad biomarker panel with retesting built into the year |
| InsideTracker | ~$249–$589 per test | Pay per test, no membership |
| Superpower | ~$499/yr membership | Broad biomarker panel presented through a consumer app |
Physician-led programs, alphabetically
| Program | Price | Model |
|---|---|---|
| Fountain Life | $19,500+/yr | In-person concierge with imaging and a broad diagnostic panel |
| Hone Health | ~$540–$2,640/yr | Telehealth hormone care with at-home collection |
| Lifeforce | ~$1,900/yr | Telehealth optimization with a bundled panel and scheduled retests |
| Marek Health | $2,500–$6,000/yr | Telehealth with an a la carte lab menu and hormone depth |
| Maximus | ~$1,800–$3,600/yr plus labs | Telehealth hormone protocols; labs generally billed separately |
| Opt Health | ~$3,000/yr | Telehealth optimization, physician-led, with scheduled reassessment |
Optional screening services, alphabetically
| Service | Price | What it is | What to know before booking |
|---|---|---|---|
| Ezra | $1,395–$2,395 per scan | Whole-body MRI | Not recommended by screening guidelines for asymptomatic adults; incidental findings are common |
| Galleri | ~$949 per test | Blood-based multi-cancer early detection | Not FDA-approved and not in screening guidelines; a negative result does not replace guideline screening |
| Prenuvo | $999–$2,499 per scan | Whole-body MRI | Same considerations as any whole-body MRI — the follow-up pathway matters more than the scan |
How to pick
- Start with what is already covered. An annual wellness visit, guideline screening, vaccinations, DEXA where indicated and a medication review carry the strongest evidence and cost little or nothing.
- Spend discretionary money on training before testing. Supervised strength and balance work is the most defensible line item in this decade.
- Add a broad panel if your existing care is not covering the markers above. A diagnostic platform gives breadth, with interpretation left to you or your physician.
- Consider a physician-led program when a specific pattern needs treating and consolidating labs, interpretation and prescribing into one relationship saves real friction.
- Approach optional scans as a decision, not a purchase. Ask what you would do with each possible result, and budget for the follow-up testing a finding would trigger.
- Keep the primary care relationship. Nothing on this page substitutes for a clinician who knows your full history and medication list.
What this audience most commonly gets wrong
- Skipping resistance training. It is the intervention with the largest effect on independence, and it is the one most often treated as optional.
- Accepting hearing loss. Correction is associated with better cognitive and fall outcomes, and untreated hearing loss is often mistaken for cognitive decline.
- Never reviewing a medication list. Polypharmacy accumulates quietly and drives falls, confusion and hospitalisations.
- Buying an unproven scan while covered screening is overdue. The evidence gap between the two is large and runs the opposite way to the price gap.
- Treating a fall as bad luck. A first fall is the strongest available predictor of the next one and should trigger a gait, vision, medication and blood-pressure review.
- Under-eating protein while trying to lose weight. Weight loss without resistance training and adequate protein costs muscle, which is the opposite of the goal.
- Chasing a biological-age score. Grip strength, gait speed, blood pressure and bone density predict more and cost less.
Realistic budget
| Spend | What it buys | What you actually get |
|---|---|---|
| $0–$200 one-off | Home blood-pressure cuff, resistance bands or dumbbells, a grip dynamometer | The highest return per dollar available at this age, by a wide margin |
| $0–$400/yr | Medicare-covered screening, an annual wellness visit, vaccinations, DEXA where indicated, a medication review | The interventions with the strongest evidence, mostly already paid for |
| $300–$1,200/yr | Supervised or group strength and balance training | The single most defensible discretionary spend in this decade |
| $250–$600/yr | A direct-to-consumer broad panel, self-interpreted, to supplement covered testing | Breadth and a trend line, with interpretation left to you or your physician |
| $540–$6,000/yr | A telehealth physician-led program with scheduled retesting and prescribing | Consolidation, where a specific pattern needs treating |
| $949–$2,499 per test | Whole-body MRI or multi-cancer blood screening | Optional and unproven for asymptomatic adults. Budget for the follow-up testing a finding would trigger, not just the scan |
| $19,500+/yr | In-person concierge with imaging and clinic access | Screening breadth and access, at the highest cost of any option here |
See a clinician promptly rather than a platform for a fall or near-fall, new confusion, unexplained weight loss, chest pain or breathlessness on exertion, blood in stool or urine, new or worsening breathlessness at rest, or any sudden change in vision, speech or strength. Those are not optimization questions, and none of them should wait for a scheduled panel.
Frequently Asked Questions
What matters most for longevity after retirement?
Muscle and balance, blood pressure, and the things that prevent a single catastrophic event. Muscle mass declines 3 to 8% per decade after 30 and faster after 60, and about one in four adults over 65 falls each year. A hip fracture carries substantial one-year mortality and is the most common route from independent living to dependence. Resistance training, balance work, protein at 1.0 to 1.2 g per kg, blood pressure control, hearing and vision correction, and guideline-based screening cover most of what is achievable.
Is whole-body MRI worth it at this age?
It is not recommended by screening guidelines for asymptomatic adults, at any age. Whole-body MRI finds a large number of incidental findings, most of which are benign and some of which lead to further imaging, biopsy, and the risks and costs those carry. It is more defensible with a specific risk factor — a strong family history, a prior cancer, a known genetic syndrome — and the conversation to have before booking is what you would actually do with each possible result.
Is testosterone therapy appropriate for older men?
It can be, with confirmed hypogonadism on two early-morning draws plus symptoms, and with monitoring of hematocrit, PSA and estradiol. The TRAVERSE trial found no increase in major adverse cardiac events in middle-aged and older men with hypogonadism and cardiovascular risk, alongside higher rates of pulmonary embolism, atrial fibrillation and acute kidney injury. It is not appropriate with active prostate cancer, an unevaluated elevated PSA, baseline hematocrit above roughly 50%, untreated severe sleep apnea, or a recent cardiovascular event.
What about hormone therapy for postmenopausal women?
The timing matters more than the formulation. Evidence supports a more favorable risk-benefit balance for systemic therapy started before age 60 or within about 10 years of the final period. Started 15 or 20 years out, the calculus differs. Low-dose vaginal estrogen for genitourinary symptoms is a separate decision, has minimal systemic absorption, and remains appropriate for many women who cannot take systemic therapy. Contraindications are real and individual, so this is a clinician conversation.
Which platforms are relevant at this stage?
For diagnostics without a clinician, the options reviewed here are, alphabetically, Function Health, InsideTracker and Superpower. For a physician who manages care and can prescribe, the programs reviewed here are, alphabetically, Fountain Life, Hone Health, Lifeforce, Marek Health, Maximus and Opt Health. For optional screening services, alphabetically, Ezra, Galleri and Prenuvo. Note that most of the highest-value testing in this decade is already covered by Medicare, and that is the place to start.
What do people in this decade most commonly get wrong?
Skipping resistance training because it feels like a young person's activity, when it is the intervention with the largest effect on independence. Accepting hearing loss as inevitable rather than correcting it. Never reviewing a medication list that has grown for twenty years. Buying an unproven scan while the covered colonoscopy is overdue. And treating a fall as bad luck rather than as the strongest available predictor of the next one.
How much does a sensible year cost?
Less than most people expect. A blood-pressure cuff and basic training equipment run under $200 once. Medicare covers an annual wellness visit, guideline screening, vaccinations and DEXA where indicated. Supervised strength and balance training runs $300 to $1,200 a year and is the most defensible discretionary spend at this age. A broad self-pay panel adds $250 to $600. Physician-led programs run $540 to $19,500 a year, and optional scans run $949 to $2,499 each before any follow-up testing.
Related
- How to lower biological age — what the scores can and cannot tell you
- HRT vs BHRT — formulation, route and timing
- Signs of low testosterone — which symptoms track the numbers
- ApoB — the cardiovascular marker standard panels omit
- Doctor-led options — every physician-supervised platform on one rubric